The Californian Supreme Court cements vigorous scrutiny of reverse-payment settlements (Cipro)

On May 7, 2015, in the first appellate reverse-payment ruling since the U.S. Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013), the California Supreme Court overturned a lower court decision granting summary judgment for defendants. On behalf of all seven Justices, Justice Kathryn Werdegar wrote an opinion that supported Actavis and filled in some of the holes left open by the U.S. Supreme Court, cementing vigorous scrutiny of agreements by which brand-name drug companies pay generics to delay entering the market. Facts The case involves Bayer’s blockbuster antibiotic Cipro. In 1987, Bayer received a patent (expiring in 2003) on the active ingredient in Cipro. In re Cipro Cases I & II, 2015 WL 2125291, at *1 (Cal. May 7, 2015). In 1991, defendant Barr

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The Californian Supreme Court cements vigorous scrutiny of reverse-payment settlements (Cipro), 7 mai 2015, e-Competitions May 2015, Art. N° 73830

Visites 316

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues